Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Egrifta (Tesamorelin Acetate) Market Forecast Highlighting Growth From $ Billion To $ Billion
The historic expansion was driven by a growing number of HIV-associated lipodystrophy cases, chronic side effects linked to antiretroviral therapy, clinical confirmation of GHRH analogs’ effectiveness, heightened recognition of visceral fat dangers, and an unfulfilled demand for precisely targeted abdominal fat reduction.
The expansion expected during the forecast period is driven by rising personalized HIV care, an expanding pipeline for peptide therapeutics, greater detection of metabolic complications, favorable reimbursement policies for specialty medications, and an emphasis on improving long-term quality of life for HIV patients. Key developments shaping this period involve the introduction of long-acting peptide treatments, individualized approaches to lipodystrophy management, broader application in metabolic conditions, patient-focused injectable therapies, and increased uptake of specialty biologic drugs.
Download A Free Sample Report For Comprehensive Market Insights:
Egrifta (Tesamorelin Acetate) Market Demand Drivers Creating New Revenue Opportunities
The upcoming growth of the egrifta (tesamorelin acetate) market is being significantly propelled by the rising number of human immunodeficiency virus (HIV) cases. These cases involve individuals infected with HIV, which gradually compromises their immune system. This increase is partly driven by limited awareness and education regarding preventive strategies like condom use and routine testing, especially among high-risk groups. By stimulating growth hormone release, egrifta helps reduce excess visceral fat and enhance body composition, thereby improving overall health and quality of life for HIV patients. For example, the Minnesota Department of Health, a state health agency in the US, reported 324 new HIV diagnoses in 2023, reflecting a 24% increase from 2022, as of May 2024. Consequently, the growing prevalence of human immunodeficiency virus (HIV) cases is fueling the egrifta (tesamorelin acetate) market’s expansion.
Egrifta (Tesamorelin Acetate) Market Segmentation Trends And Revenue Drivers
The egrifta (tesamorelin acetate) market covered in this report is segmented –
1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By End-Users: Hospitals, Specialized Clinics, Home Care
Egrifta (Tesamorelin Acetate) Market Trends Driving Strategic Industry Expansion
The key trend in the egrifta (tesamorelin acetate) market is focusing on developing advanced synthetic peptide drugs to enhance the effectiveness of treatments for HIV-related lipodystrophy. Synthetic peptide drugs are artificially designed compounds that aim to deliver specific therapeutic effects by mimicking or enhancing the action of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced that production of EGRIFTA SV has resumed following a voluntary shutdown of its contract manufacturer’s facility due to FDA inspection observations. A newly manufactured batch has completed quality control and will be released upon US Food and Drug Administration (FDA) approval of a prior approval supplement, and two additional batches are in production. The company is managing inventory to meet patient demand until mid-January 2025 and is working with the FDA to prevent a shortage in 2025. EGRIFTA SV is distributed only in the United States.
Egrifta (Tesamorelin Acetate) Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.
Access The Complete Egrifta (Tesamorelin Acetate) Market Report:
Egrifta (Tesamorelin Acetate) Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model